A 28-amino-acid neuropeptide with extremely broad receptor distribution — VPAC1 and VPAC2 receptors are expressed in the gut, lungs, cardiovascular system, immune cells, and CNS. VIP functions as a potent vasodilator, bronchodilator, and anti-inflammatory agent. Its ultrashort half-life (~1 minute) in plasma reflects rapid DPP-IV and neutral endopeptidase degradation. Investigated in pulmonary hypertension, inflammatory bowel disease, and chronic inflammatory respiratory disease models.
Research FocusPulmonary hypertension, inflammatory bowel disease, airway relaxation, neuroprotection
ReconstitutionSterile water — 100 mcg/mL; protect from light
Stability7 days at 2–8°C; extremely light-sensitive
Key distinction: The most pleiotropic neuropeptide in the mammalian body — VPAC receptors on virtually every tissue type make VIP the broadest-acting endogenous peptide, but its 1-minute half-life severely limits systemic delivery.
Scientific Evidence
Published Research
[1]
Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;169:1217-1218 — PubMed 5450698
[2]
Petkov V et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346 — PubMed 12727925
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.